Avenue Therapeutics (ATXI) Short Interest Ratio & Short Volume $0.24 +0.01 (+4.65%) As of 04/30/2025 01:53 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Avenue Therapeutics Short Interest DataAvenue Therapeutics (ATXI) has a short interest of 51,400 shares, representing 2.95% of the float (the number of shares available for trading by the public). This marks a -13.90% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 139,960 shares to cover all short positions.Current Short Interest51,400 sharesPrevious Short Interest59,700 sharesChange Vs. Previous Month-13.90%Dollar Volume Sold Short$43,587.20Short Interest Ratio0.1 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares3,150,000 sharesFloat Size1,740,000 sharesShort Percent of Float2.95%Today's Trading Volume2,134 sharesAverage Trading Volume139,960 sharesToday's Volume Vs. Average2% Short Selling Avenue Therapeutics? Sign up to receive the latest short interest report for Avenue Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATXI Short Interest Over TimeATXI Days to Cover Over TimeATXI Percentage of Float Shorted Over Time Avenue Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202551,400 shares $43,587.20 -13.9%3.0%0.1 $0.85 2/28/202559,700 shares $65,670.00 -35.3%3.4%0.2 $1.10 2/15/202592,200 shares $125,392.00 -40.5%5.3%0.2 $1.36 1/31/2025154,900 shares $210,664.00 +92.2%8.9%0.4 $1.36 1/15/202580,600 shares $153,140.00 +258.2%4.6%0.2 $1.90 12/31/202422,500 shares $45,000.00 -35.9%1.3%0.5 $2.00 12/15/202435,100 shares $63,180.00 -25.0%1.9%0.8 $1.80 11/30/202446,800 shares $100,432.80 +6.1%2.7%1.1 $2.15 11/15/202444,100 shares $85,113.00 -13.4%2.4%1 $1.93 10/31/202450,900 shares $123,178.00 +85.8%3.7%1.1 $2.42 Get the Latest News and Ratings for ATXI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202427,400 shares $57,266.00 -13.0%2.0%0.5 $2.09 9/30/202431,500 shares $78,435.00 +107.2%2.3%0.7 $2.49 9/15/202415,200 shares $42,712.00 -58.6%1.1%0.3 $2.81 8/31/202436,700 shares $93,218.00 -22.3%2.8%0.8 $2.54 8/15/202447,200 shares $121,974.24 -5.0%3.6%1 $2.58 7/31/202449,700 shares $139,160.00 +21.8%5.7%1 $2.80 7/15/202440,800 shares $141,576.00 +3.8%4.7%0.6 $3.47 6/30/202439,300 shares $137,550.00 -7.3%4.5%0.6 $3.50 6/15/202442,400 shares $157,304.00 -14.3%4.9%0.7 $3.71 5/31/202449,500 shares $170,280.00 +7.4%6.0%0.8 $3.44 5/15/202446,100 shares $168,265.00 +169.6%5.6%0.7 $3.65 4/30/202417,100 shares $85,671.00 -91.2%3.3%0.3 $5.01 4/15/2024193,600 shares $24,200.00 -31.6%N/A0.1 $0.13 3/31/2024283,100 shares $41,757.25 -9.7%N/A0.1 $0.15 3/15/2024313,400 shares $49,360.50 +91.7%N/A0.1 $0.16 2/29/2024163,500 shares $24,802.95 -51.6%N/A0 $0.15 2/15/2024337,700 shares $49,743.21 -50.1%N/A0.1 $0.15 1/31/2024677,300 shares $100,240.40 -39.0%N/A0.1 $0.15 1/15/20241,110,000 shares $193,140.00 +378.9%N/A0.2 $0.17 12/31/2023231,800 shares $37,319.80 +1.2%3.1%0 $0.16 12/15/2023229,100 shares $33,906.80 -65.6%2.4%0.1 $0.15 11/30/2023665,300 shares $141,043.60 +329.8%9.2%0.4 $0.21 11/15/2023154,800 shares $28,730.88 -69.9%1.6%0.8 $0.19 10/31/2023513,700 shares $120,719.50 +39.0%7.7%3.3 $0.24 10/15/2023369,700 shares $221,746.06 +73.2%5.6%5.7 $0.60 9/30/2023213,400 shares $150,873.80 +699.3%3.3%2.9 $0.71 9/15/202326,700 shares $22,134.30 +184.0%0.5%0.4 $0.83 8/31/20239,400 shares $7,294.40 -69.9%0.1%0.2 $0.78 8/15/202331,200 shares $31,200.00 -47.7%0.5%0.5 $1.00 7/31/202359,600 shares $62,580.00 -12.2%0.9%0.8 $1.05How to invest in Elon Musk’s Optimus before its launch (Ad)Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that Elon Musk himself believes "will be the biggest product ever of any kind". One well-connected Silicon Valley insider has uncovered a way for anybody to claim a stake in Optimus with as little as $100. All you'll need is a regular brokerage account.Get all the information here. 7/15/202367,900 shares $81,276.30 -45.9%1.1%0.7 $1.20 6/30/2023125,400 shares $144,210.00 -4.7%2.0%0.6 $1.15 6/15/2023131,600 shares $152,656.00 -32.7%2.1%0.5 $1.16 5/31/2023195,500 shares $211,140.00 -35.0%3.3%0.5 $1.08 5/15/2023300,700 shares $321,749.00 -16.3%5.1%0.6 $1.07 4/30/2023359,100 shares $341,109.09 +49.8%5.2%0.7 $0.95 4/15/2023239,700 shares $261,273.00 -16.6%3.9%0.4 $1.09 3/31/2023287,300 shares $334,704.50 -36.7%4.8%0.3 $1.17 3/15/2023453,900 shares $531,063.00 +208.8%7.5%0.5 $1.17 2/28/2023147,000 shares $163,170.00 -10.7%2.4%0.2 $1.11 2/15/2023164,600 shares $204,104.00 -42.8%2.7%0.2 $1.24 1/31/2023287,500 shares $396,750.00 +229.0%6.6%0.3 $1.38 1/15/202387,400 shares $106,628.00 -16.4%2.1%0.1 $1.22 12/30/2022104,500 shares $121,220.00 -17.1%2.4%0 $1.16 12/15/2022126,100 shares $156,364.00 -8.5%2.8%0 $1.24 11/30/2022137,800 shares $184,652.00 +66.2%3.1%0 $1.34 11/15/202282,900 shares $137,614.00 -61.0%1.9%0 $1.66 10/31/2022212,600 shares $508,114.00 +1,463.2%5.6%0.1 $2.39 10/15/202213,600 shares $45,288.00 -97.4%0.4%0 $3.33 9/30/2022524,700 shares $5.29 million +1,836.2%69.5%0.2 $10.08 9/15/202227,100 shares $108,535.50 -82.1%N/A0.1 $4.01 8/31/2022151,200 shares $36,408.96 +91.4%1.3%0.5 $0.24 8/15/202279,000 shares $23,091.70 +28.5%0.7%0.3 $0.29 7/31/202261,500 shares $15,768.60 +104.3%0.5%0.2 $0.26 7/15/202230,100 shares $8,033.69 -61.2%0.3%0.1 $0.27 6/30/202277,600 shares $20,897.68 -17.5%0.7%0.2 $0.27 6/15/202294,000 shares $25,192.00 +50.9%0.8%0.3 $0.27 5/31/202262,300 shares $17,444.00 -31.9%0.6%0.1 $0.28 5/15/202291,500 shares $30,927.00 +10.5%0.8%0 $0.34 4/30/202282,800 shares $30,611.16 +212.5%0.8%0 $0.37 4/15/202226,500 shares $12,725.30 +108.7%0.2%0 $0.48 3/31/202212,700 shares $6,115.05 -98.1%0.1%0 $0.48 3/15/2022674,600 shares $467,497.80 +177.6%6.7%0.1 $0.69 2/28/2022243,000 shares $82,595.70 +2.3%2.4%0.1 $0.34 2/15/2022237,600 shares $144,936.00 -43.0%2.4%0.4 $0.61 1/31/2022416,900 shares $304,753.90 -15.0%4.1%0.8 $0.73 1/15/2022490,300 shares $431,464.00 -3.0%5.4%1 $0.88 12/31/2021505,600 shares $459,084.80 -23.7%6.2%1 $0.91 12/15/2021662,500 shares $602,875.00 +515.7%8.1%1.4 $0.91 11/30/2021107,600 shares $151,716.00 -20.2%1.2%0.3 $1.41 11/15/2021134,800 shares $184,676.00 -50.2%1.8%1.3 $1.37 10/29/2021270,500 shares $427,390.00 +21.1%4.1%4.2 $1.58 10/15/2021223,300 shares $283,591.00 -10.8%3.4%3.4 $1.27 9/30/2021250,200 shares $372,798.00 -10.1%3.8%3 $1.49 9/15/2021278,400 shares $462,144.00 -1.7%4.2%2 $1.66 8/31/2021283,300 shares $512,773.00 +6.7%4.3%1 $1.81 8/13/2021265,400 shares $453,834.00 -13.8%4.0%0.9 $1.71 7/30/2021308,000 shares $551,320.00 -27.0%4.7%1 $1.79 7/15/2021421,800 shares $873,126.00 +17.8%6.4%1.3 $2.07 6/30/2021358,100 shares $898,831.00 -28.0%5.4%0.9 $2.51Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 6/15/2021497,000 shares $1.39 million -4.5%7.5%1.2 $2.80 5/28/2021520,500 shares $2.58 million -2.3%7.9%1.8 $4.96 5/14/2021532,500 shares $2.22 million -13.8%8.0%1.6 $4.16 4/30/2021617,400 shares $3.24 million 0.0%9.3%1.8 $5.24 4/15/2021617,500 shares $2.95 million +37.6%9.3%2 $4.77 3/31/2021448,700 shares $2.58 million +11.5%6.8%1.8 $5.75 3/15/2021402,500 shares $2.75 million +12.8%6.1%1.5 $6.84 2/26/2021357,000 shares $1.76 million -6.9%5.4%0.9 $4.94 2/12/2021383,600 shares $2.62 million -17.9%5.8%1 $6.83 1/29/2021467,000 shares $2.81 million -11.2%7.0%1.2 $6.01 1/15/2021526,000 shares $3.31 million -12.4%7.9%1.4 $6.30 12/31/2020600,600 shares $3.48 million +73.7%9.0%1.1 $5.80 12/15/2020345,800 shares $1.25 million +13.0%5.2%0.6 $3.62 11/30/2020306,100 shares $1.04 million -7.2%4.6%1 $3.41 11/15/2020329,900 shares $1.09 million +9.8%5.0%1.2 $3.29 10/30/2020300,500 shares $955,590.00 +4.1%4.5%1.1 $3.18 10/15/2020288,800 shares $1.15 million +110.7%4.4%1.2 $3.98 9/30/2020137,100 shares $1.48 million -8.1%2.1%3 $10.83 9/15/2020149,200 shares $1.78 million +0.8%2.3%2.9 $11.96 8/31/2020148,000 shares $1.65 million -13.7%2.2%3.1 $11.13 8/14/2020171,400 shares $1.82 million -34.4%2.6%3.2 $10.59 7/31/2020261,200 shares $2.65 million +13.6%4.0%4.6 $10.13 7/15/2020230,000 shares $2.21 million +12.1%3.5%3.6 $9.60 6/30/2020205,200 shares $2.27 million +316.2%3.1%3.2 $11.08 6/15/202049,300 shares $530,468.00 +31.1%0.8%1 $10.76 5/29/202037,600 shares $431,272.00 -4.6%0.6%0.6 $11.47 5/15/202039,400 shares $386,514.00 +33.6%0.6%0.6 $9.81 ATXI Short Interest - Frequently Asked Questions What is Avenue Therapeutics' current short interest? Short interest is the volume of Avenue Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 51,400 shares of ATXI short. 2.95% of Avenue Therapeutics' shares are currently sold short. Learn More on Avenue Therapeutics' current short interest. What is a good short interest percentage for Avenue Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.95% of Avenue Therapeutics' floating shares are currently sold short. Is Avenue Therapeutics' short interest increasing or decreasing? Avenue Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 51,400 shares, a drop of 13.9% from the previous total of 59,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Avenue Therapeutics' float size? Avenue Therapeutics currently has issued a total of 3,150,000 shares. Some of Avenue Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Avenue Therapeutics currently has a public float of 1,740,000 shares. How does Avenue Therapeutics' short interest compare to its competitors? 2.95% of Avenue Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Avenue Therapeutics: Palisade Bio, Inc. (1.22%), Kazia Therapeutics Limited (0.27%), Organovo Holdings, Inc. (4.32%), Hepion Pharmaceuticals, Inc. (5.93%), SciSparc Ltd. (4.50%), Virax Biolabs Group Limited (6.39%), Enveric Biosciences, Inc. (7.51%), RedHill Biopharma Ltd. (2.09%), Synaptogenix, Inc. (0.10%), Revelation Biosciences, Inc. (13.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), Strategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Avenue Therapeutics stock? Short selling ATXI is an investing strategy that aims to generate trading profit from Avenue Therapeutics as its price is falling. ATXI shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Avenue Therapeutics? A short squeeze for Avenue Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATXI, which in turn drives the price of the stock up even further. How often is Avenue Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATXI, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies PALI Short Squeeze KZIA Short Squeeze ONVO Short Squeeze HEPA Short Squeeze SPRC Short Squeeze VRAX Short Squeeze ENVB Short Squeeze RDHL Short Squeeze SNPX Short Squeeze REVB Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATXI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATXI Stock Free ATXI Stock Alerts